Challenges and opportunities of defining clinical leptin resistance

Martin G. Myers; Steven B. Heymsfield; Carol Haft; Barbara B. Kahn; Maren Laughlin; Rudolph L. Leibel; Matthias H. Tschöp; Jack A. Yanovski

doi:10.1016/j.cmet.2012.01.002

Challenges and opportunities of defining clinical leptin resistance

Martin G. Myers, Steven B. Heymsfield, Carol Haft, Barbara B. Kahn, Maren Laughlin, Rudolph L. Leibel, Matthias H. Tschöp, Jack A. Yanovski

Research output: Contribution to journal › Review article › peer-review

201 Scopus citations

Abstract

The widespread use of the inadequately defined term "leptin resistance" led the National Institutes of Health to convene a workshop aimed at developing a quantitative definition of this term that would facilitate mechanistic research into leptin's actions in human health and disease. Although leptin-responsive conditions are recognized, the field is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of the hormone's action. Further advances require biomarkers that can be used to identify patients who may benefit from leptin therapy and that are useful for understanding the determinants of clinical leptin responsiveness.

Original language	English
Pages (from-to)	150-156
Number of pages	7
Journal	Cell Metabolism
Volume	15
Issue number	2
DOIs	https://doi.org/10.1016/j.cmet.2012.01.002
State	Published - 8 Feb 2012
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cmet.2012.01.002

Cite this

@article{5541a1b1e9d34666affc3766a8655420,

title = "Challenges and opportunities of defining clinical leptin resistance",

abstract = "The widespread use of the inadequately defined term {"}leptin resistance{"} led the National Institutes of Health to convene a workshop aimed at developing a quantitative definition of this term that would facilitate mechanistic research into leptin's actions in human health and disease. Although leptin-responsive conditions are recognized, the field is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of the hormone's action. Further advances require biomarkers that can be used to identify patients who may benefit from leptin therapy and that are useful for understanding the determinants of clinical leptin responsiveness.",

author = "Myers, {Martin G.} and Heymsfield, {Steven B.} and Carol Haft and Kahn, {Barbara B.} and Maren Laughlin and Leibel, {Rudolph L.} and Tsch{\"o}p, {Matthias H.} and Yanovski, {Jack A.}",

note = "Funding Information: This conference was supported by the National Institute of Diabetes and Digestive and Kidney Diseases. ",

year = "2012",

month = feb,

day = "8",

doi = "10.1016/j.cmet.2012.01.002",

language = "English",

volume = "15",

pages = "150--156",

journal = "Cell Metabolism",

issn = "1550-4131",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Challenges and opportunities of defining clinical leptin resistance

AU - Myers, Martin G.

AU - Heymsfield, Steven B.

AU - Haft, Carol

AU - Kahn, Barbara B.

AU - Laughlin, Maren

AU - Leibel, Rudolph L.

AU - Tschöp, Matthias H.

AU - Yanovski, Jack A.

N1 - Funding Information: This conference was supported by the National Institute of Diabetes and Digestive and Kidney Diseases.

PY - 2012/2/8

Y1 - 2012/2/8

N2 - The widespread use of the inadequately defined term "leptin resistance" led the National Institutes of Health to convene a workshop aimed at developing a quantitative definition of this term that would facilitate mechanistic research into leptin's actions in human health and disease. Although leptin-responsive conditions are recognized, the field is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of the hormone's action. Further advances require biomarkers that can be used to identify patients who may benefit from leptin therapy and that are useful for understanding the determinants of clinical leptin responsiveness.

AB - The widespread use of the inadequately defined term "leptin resistance" led the National Institutes of Health to convene a workshop aimed at developing a quantitative definition of this term that would facilitate mechanistic research into leptin's actions in human health and disease. Although leptin-responsive conditions are recognized, the field is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of the hormone's action. Further advances require biomarkers that can be used to identify patients who may benefit from leptin therapy and that are useful for understanding the determinants of clinical leptin responsiveness.

UR - http://www.scopus.com/inward/record.url?scp=84856975510&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2012.01.002

DO - 10.1016/j.cmet.2012.01.002

M3 - Review article

C2 - 22326217

AN - SCOPUS:84856975510

SN - 1550-4131

VL - 15

SP - 150

EP - 156

JO - Cell Metabolism

JF - Cell Metabolism

IS - 2

ER -

Challenges and opportunities of defining clinical leptin resistance

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this